Linked Life Data

16503749

Source:http://linkedlifedata.com/resource/pubmed/id/16503749

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-2-28
pubmed:abstractText
Despite the significant gains made in the treatment of many cancers over the last few decades, further improvements in survival using traditional chemotherapeutic agents have now begun to plateau. The development of bevacizumab, a monoclonal antibody targeted against the vascular endothelial growth factor, has provided promise for continued gains in survival in the therapy of a variety of cancers, including some previously refractory to traditional chemotherapeutic agents. Although its toxicity profile differs from traditional chemotherapeutic drugs, bevacizumab is not completely without side effects. The mechanisms of its unique toxicities have not yet been fully characterised, and at this time it is not possible to predict which toxicities will be experienced by each individual patient or which population.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1744-764X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
289-301
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
The safety of bevacizumab.
pubmed:affiliation
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University Cancer Institute, Mail Code L586, Portland, OR 97239-3098, USA. sanbornr@ohsu.edu
pubmed:publicationType
Journal Article, Review